胰岛素强化治疗后转换为司美格鲁肽联合基础胰岛素治疗2型糖尿病1例被引量：2

Type 2 diabetes mellitus patients switched to semaglutide combined with basal insulin after intensive insulin therapy:a case report

原文传递

导出

摘要回顾性分析1例在新疆医科大学第一附属医院内分泌科既往明确诊断的2型糖尿病患者使用胰岛素强化治疗后,转换为司美格鲁肽联合基础胰岛素序贯治疗的诊疗过程并进行文献复习。患者为57岁男性,因“发现血糖升高9年,血糖波动15 d”入院,患者体形偏胖、血糖较高、依从性较差,既往已胰岛素联合口服降糖药治疗>3个月,入院测糖化血红蛋白9.10%。给予胰岛素泵联合口服降糖药物治疗,逐步简化方案为司美格鲁肽联合德谷胰岛素,二甲双胍0.5 g、3次/d,卡格列净100 mg、1次/d治疗,血糖控制平稳后出院。司美格鲁肽是一种可与胰岛素及口服降糖药物联合使用,具有降糖、减重作用的新型胰高糖素样肽-1受体激动剂,可用于2型糖尿病患者胰岛素强化治疗后的序贯治疗。

作者杨靖蒋升 Yang Jing;Jiang Sheng(Department of Endocrinology,First Affiliated Hospital of Xinjiang Medical University,Urumqi 830017,China)

机构地区新疆医科大学第一附属医院内分泌科

出处《中华糖尿病杂志》 CAS CSCD 北大核心 2022年第S01期52-54,共3页 CHINESE JOURNAL OF DIABETES MELLITUS

关键词糖尿病 2型司美格鲁肽胰岛素强化治疗

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献4

1张雪莲.对ADA/EASD以患者为中心高血糖管理路径2015更新的解读[J].糖尿病天地（临床）,2015,9(4):186-193. 被引量：49
2母义明.由理论到实践——短期胰岛素强化治疗调量方案及出院后序贯方案新循证[J].中国糖尿病杂志,2022,30(5):398-400. 被引量：3
3刘静,朱大龙,中华医学会糖尿病学分会基层糖尿病防治学组.基层口服降糖药物联合及起始胰岛素治疗2型糖尿病中国专家共识[J].中国糖尿病杂志,2022,30(5):321-331. 被引量：33
4纪立农.胰高血糖素样肽1受体激动剂周制剂中国证据与专家指导建议[J].中国糖尿病杂志,2022,30(6):405-411. 被引量：45

二级参考文献83

1Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes:a patient centered approach Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2012.35,1364-1379.
2lnzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2012,55:1577 1596.
3Stratton IM, Adler AI, Nell HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000, 321:405-412.
4UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998 352:837 853.
5Holman RR, Paul SK, Bethel MA, Matthews DR, Neff HA 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359:1577 1589.
6Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008, 358:2545-2559.
7Vasilakou D, Karagiannls T, Athanasiadou E, et al. Sodium glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review andmetaanalysis. Ann Intern Med, 2013 159:262-274.
8StenlSf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab, 2013, 15:372 382.
9Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52 week randomized trial. Diabetes Care 2013, 36:2508-2515.
10Roden M, Weng J, Eilbracbt J, et al. EMPAREG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double blind, placebo-controlled, phase 3 trial Lancet Diabetes Endocrinol, 2013, 1:208-219.